Latest Interim Results News

Page 4 of 15
Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.
Ada Torres
Ada Torres
2 Mar 2026
Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.
Ada Torres
Ada Torres
27 Feb 2026
Synertec Corporation Limited reported a 20% increase in revenue to $10.2 million for the half-year ended 31 December 2025, alongside a 40% improvement in net loss after tax. The company’s Powerhouse renewable energy system continues to gain traction, supported by strategic partnerships and expanded manufacturing.
Maxwell Dee
Maxwell Dee
27 Feb 2026
Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.
Ada Torres
Ada Torres
27 Feb 2026
MOVE Logistics Group reports a 98% improvement in normalised earnings before tax and a significant reduction in net debt, positioning the company on track for a profitable FY26 despite ongoing market challenges.
Victor Sage
Victor Sage
27 Feb 2026
KKR Credit Income Fund reported a $7.1 million operating profit for the half-year ending December 2025, down sharply from last year, while reinstating its Distribution Reinvestment Plan and maintaining steady monthly distributions.
Victor Sage
Victor Sage
26 Feb 2026
NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.
Ada Torres
Ada Torres
25 Feb 2026
Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.
Ada Torres
Ada Torres
25 Feb 2026
EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.
Ada Torres
Ada Torres
25 Feb 2026
Meridian Energy has reported a robust turnaround with a NZD 227 million net profit after tax for the first half of 2026, driven by record wind generation and strong hydro inflows. The company also raised its interim dividend and advanced multiple renewable projects.
Maxwell Dee
Maxwell Dee
25 Feb 2026
The Agency Group Australia Ltd has reported a solid half-year performance with revenue rising 18% to $57.1 million and a 34% jump in gross commission income. The company narrowed its net loss and improved EBITDA, driven by strong sales and agent recruitment.
Eva Park
Eva Park
24 Feb 2026
Tyro Payments Limited reported a solid 5% increase in gross profit and a 72% surge in statutory profit before tax for H1 FY26, underpinned by growth in core payment volumes and banking activities. The company also expanded its fintech footprint with the acquisition of AI-powered platform Thriday.
Claire Turing
Claire Turing
24 Feb 2026

Browse the archive

Full archive